Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XENE Xenon Pharmaceuticals

Trading 03-27 10:58:08 EDT

55.10

-0.43

-0.77%

High55.59	Low54.61	Vol197.19K
Open55.44	D1 Closing55.53	Amplitude1.76%
Mkt Cap5.26B	Tradable Cap4.95B	Total Shares95.43M
T/O10.87M	T/O Rate0.22%	Tradable Shares89.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XENE","market":"US","secType":"STK","nameCN":"Xenon Pharmaceuticals","latestPrice":55.1,"timestamp":1774623480009,"preClose":55.53,"halted":0,"volume":197186,"delay":0,"changeRate":-0.007743562038537722,"floatShares":89889500,"shares":95427200,"eps":-4.364588,"marketStatus":"Trading","change":-0.43,"latestTime":"03-27 10:58:08 EDT","open":55.44,"high":55.59,"low":54.6101,"amount":10870417.55371,"amplitude":0.017646,"askPrice":55.41,"askSize":34,"bidPrice":55.12,"bidSize":110,"shortable":3,"etf":0,"ttmEps":-4.364588,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774641600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1415163600000,"exchange":"NASDAQ","adjPreClose":55.53,"preHourTrading":{"tag":"盘前","latestPrice":55.5,"preClose":55.53,"latestTime":"08:38 EDT","volume":58,"amount":3201.1899399999998,"timestamp":1774615138719,"change":-0.03,"changeRate":-0.00054,"amplitude":0.016568},"postHourTrading":{"tag":"盘后","latestPrice":55.53,"preClose":55.53,"latestTime":"19:58 EDT","volume":18878,"amount":1048300.22,"timestamp":1774569496812,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.580992,"impliedVol":0.4443,"impliedVolPercentile":0.3546},"requestUrl":"/m/hq/s/XENE/tweets","defaultTab":"tweets","newsList":[{"id":"2619361463","title":"Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2619361463","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619361463?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:38","pubTimestamp":1773664680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 08:38 ET (12:38 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2619457513","title":"Xenon Pharmaceuticals Inc : Wedbush Cuts Target Price to $63 From $64","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457513?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:17","pubTimestamp":1773659841,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40402K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2619452842","title":"Wedbush Trims Price Target on Xenon Pharmaceuticals to $63 From $64, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452842","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452842?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:54","pubTimestamp":1773658481,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) has an average rating of buy and mean price target of $79.19, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"gpt_icon":0},{"id":"2619480689","title":"H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619480689","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619480689?lang=en_us&edition=fundamental","pubTime":"2026-03-16 10:15","pubTimestamp":1773627316,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Xenon, with a price target of $74.00. According to Tip...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2619723155","title":"Xenon Pharmaceuticals Closes $747.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2619723155","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619723155?lang=en_us&edition=fundamental","pubTime":"2026-03-13 05:45","pubTimestamp":1773351918,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) said late Thursday it has closed its underwritten public offering of 12.2 million common shares, including the full exercise of the overallotment option, and pre-funded warrants to buy up to 877,194 shares, for gross proceeds of $747.5 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE","BK4139"],"gpt_icon":0},{"id":"2619152029","title":"Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2619152029","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619152029?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:01","pubTimestamp":1773345660,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia and BOSTON, MA, March  12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3255083/33485/en/Xenon-Pharmaceuticals-Announces-Closing-of-747-5-Million-Upsized-Public-Offering-Including-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","BK4139","XENE"],"gpt_icon":0},{"id":"2618597413","title":"Xenon Pharmaceuticals President and CEO Ian Mortimer Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618597413","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618597413?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271263,"startTime":"0","endTime":"0","summary":"Ian Mortimer, President and CEO and a director of Xenon Pharmaceuticals Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL6W8hRy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon Pharmaceuticals President and CEO Ian Mortimer Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139"],"gpt_icon":0},{"id":"2618947276","title":"BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Nike, Unifirst","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947276","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618947276?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:57","pubTimestamp":1773233879,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Nike, UnifirstWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL6N3ZZ0RW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","IE00BMPRXQ63.HKD","LU0251142724.SGD","LU0353189680.USD","LU0889565833.HKD","IE0009356076.USD","IE00BLSP4239.USD","LU0878866978.SGD","LU0320765489.SGD","LU1989764664.SGD","LU2506951958.HKD","IE00BLSP4452.SGD","LU0861579265.USD","LU2054465674.USD","LU0433182093.SGD","LU1267930813.SGD","LU0444973449.USD","LU0553294199.USD","BK4210","LU2896262040.SGD","IE00B3S45H60.SGD","LU1223082196.USD","CPB","ORCX","LU0234570918.USD","LU0957808578.USD","LU1934455863.HKD","LU1852331112.SGD","IE00B2Q91V27.USD","LU0823411888.USD","LU0719512351.SGD","LU0949170772.SGD","LU2237957811.SGD","LU0889566641.SGD","LU0648001328.SGD","IE00BMPRXR70.SGD","KOS","SVM","BK4212","LU0175139822.USD","LU2458330169.SGD","IE00BGHQF524.EUR","LU0417517546.SGD","LU0048573561.USD","BK4558","LU0786609619.USD","LU0081259029.USD","LU1035773651.USD","LU2087625088.SGD","LU2360106780.USD","BK4137","BK4566","LU0661504455.SGD","LU2506952170.USD","BK4139","BK4097","ORCL","LU0823417737.USD","IE00B5949003.HKD","LU1506573853.SGD","LU1548497426.USD","SG9999003800.SGD","LU2237957902.USD","UNF","LU0208291251.USD","LU0130102774.USD","BK4516","LU1366333091.USD","LU0348723411.USD","LU0476273544.USD","IE00BN8TJ469.HKD","LU0198837287.USD","LU0965509283.SGD","LU1435385759.SGD","LU1989772840.SGD","LU0323591593.USD","LU2326559502.SGD","LU0251131958.USD","BK4581","LU1003077747.HKD","LU0210536198.USD","LU0980610538.SGD","LU1934455194.USD","BK4543","IE00B7SZLL34.SGD","LU0157215616.USD","LU2746668974.SGD","CDE","IE00BYQQ9H92.USD","BK4570","LU2506952097.USD","LU1429558221.USD","LU1803068979.SGD","LU1720051017.SGD","IE00B3CCJ963.GBP","LU2357305700.SGD","IE00B19Z3B42.SGD","LU1366192091.USD","LU2108987350.USD","LU0029864427.USD","IE00BMPRXN33.USD","LU1935043536.SGD","ORCS","LU0345780521.USD","IE0004445239.USD","LU1935043023.USD","LU0353189763.USD","LU1935042215.USD","LU1201861249.SGD","LU0068578508.USD","LU1037948897.HKD","LU0738911758.USD","BK4538","IE00BFXG0V08.USD","LU1642822529.SGD","LU0708994859.HKD","BK4585","LU0965509101.SGD","LU0314106906.USD","LU0070302665.USD","LU1489326972.SGD","LU2860962120.EUR","LU2458330243.SGD","LU0545039389.USD","LU0256863811.USD","BK4533","BK4146","LU0310800379.SGD","XENE","LU0985489474.SGD","BK4588","BK4597","LU0792757196.USD","BK4528","LU0965509010.AUD","BK4534","LU1989772923.USD","LU1691799644.USD","LU0109392836.USD","LU0444971666.USD","BK4017","SG9999011175.SGD","LU0289960550.SGD","LU2746668461.USD","DTIL","LU0345780281.USD","ORCU","LU0082616367.USD","LU0056508442.USD","IE00B19Z3581.USD","IE0002270589.USD","LU2236285917.USD","BK4007","LU1069347547.HKD","LU0965508806.USD","LU1935042991.SGD","NKE","HL","LU1223083913.SGD","LU1223082519.USD","LU1303367103.USD","IE00BBT3K403.USD","LU1989764748.USD","LU1037948541.HKD","BK4213","LU0742534661.SGD","LU1267930573.SGD","LU0128525929.USD","LU2250418816.HKD","KALA","LU0823417653.USD","LU0950375773.USD","LU1815336760.USD","SG9999001424.SGD","IE00B775SV38.USD","LU2506951875.HKD","LU1934455277.USD","LU2098885051.SGD","LU1935042488.USD","FANG","LU1720051108.HKD","LU2543165471.USD","LU0234572021.USD"],"gpt_icon":1},{"id":"2618394345","title":"Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2618394345","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618394345?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:00","pubTimestamp":1773223216,"startTime":"0","endTime":"0","summary":"The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Bla...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-10-5m-share-spot-secondary-priced-at-57-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-10-5m-share-spot-secondary-priced-at-57-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1917777945.USD","BK4566","LU2505996509.AUD","LU0345770308.USD","LU1551013425.SGD","LU2237443465.HKD","LU0787776722.HKD","LU0868494708.USD","LU0238689110.USD","LU0170899867.USD","IE00BBT3K403.USD","IE00B1XK9C88.USD","XENE","LU0211331839.USD","LU2430703251.USD","LU1244550494.USD","LU2106854487.HKD","JPMO","LU0820562030.AUD","LU0211328371.USD","LU2756315318.SGD","IE00BJTD4N35.SGD","LU0203347892.USD","LU0345770993.USD","LU0820561909.HKD","LU0215105999.USD","LU1914381329.SGD","LU0345769128.USD","LU2417539215.USD","IE00BKVL7J92.USD","LU1548497426.USD","LU0820561818.USD","LU0964807845.USD","LU1496350171.SGD","BK4581","LU2213496289.HKD","BK4533","BK4534","IE00BLSP4239.USD","LU0868494617.USD","LU2552382215.SGD","LU2592432038.USD","IE00BJLML261.HKD","LU0256863811.USD","LU2552382132.HKD","LU0070302665.USD","LU0323591593.USD","LU1064131342.USD","LU0006306889.USD"],"gpt_icon":0},{"id":"2618999137","title":"Xenon Pharmaceuticals prices upsized USD 650 million public offering at USD 57 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2618999137","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618999137?lang=en_us&edition=fundamental","pubTime":"2026-03-11 10:39","pubTimestamp":1773196788,"startTime":"0","endTime":"0","summary":"Xenon priced an upsized underwritten public offering of 10.53 million common shares at USD 57 per share. The offering also includes pre-funded warrants to purchase up to 0.88 million common shares at USD 57 per warrant. Gross proceeds are expected to be about USD 650 million, before underwriting discounts and offering expenses. The underwriters have a 30-day option to buy up to 1.71 million additional common shares at the public offering price. A preliminary prospectus supplement and accompanying prospectus were filed with the SEC and are available at www.sec.gov.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL61rHj9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","XENE","BK4112","NDAQ","BK4588","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","BK4139","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2618991347","title":"Xenon Pharmaceuticals Inc - Common Shares Offered at $57.00 per Share; Pre-Funded Warrants at $56.9999","url":"https://stock-news.laohu8.com/highlight/detail?id=2618991347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618991347?lang=en_us&edition=fundamental","pubTime":"2026-03-11 10:39","pubTimestamp":1773196772,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA503XH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2618189959","title":"Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618189959","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618189959?lang=en_us&edition=fundamental","pubTime":"2026-03-10 22:15","pubTimestamp":1773152122,"startTime":"0","endTime":"0","summary":"David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on Xenon. The associated price target is $74.00. David Martin PhD has giv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-buy-rating-backed-by-superior-x-tole2-phase-3-results-and-commercial-upside-for-azetukalner-in-focal-epilepsy-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-buy-rating-backed-by-superior-x-tole2-phase-3-results-and-commercial-upside-for-azetukalner-in-focal-epilepsy-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE","SPN"],"gpt_icon":0},{"id":"2618934626","title":"Wells Fargo Sticks to Their Buy Rating for Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934626?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:58","pubTimestamp":1773140329,"startTime":"0","endTime":"0","summary":"In a report released today, Benjamin Burnett from Wells Fargo maintained a Buy rating on Xenon, with a price target of $68.00. Burnett covers the H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-buy-rating-for-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-buy-rating-for-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2618475939","title":"Wedbush Adjusts PT on Xenon Pharmaceuticals to $64 From $47, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618475939","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618475939?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:28","pubTimestamp":1773138497,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) has an average rating of buy and mean price target of $77.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"gpt_icon":0},{"id":"2618674240","title":"Small U.S. Stocks Close Up; Xenon Pharmaceuticals Climbs Highest","url":"https://stock-news.laohu8.com/highlight/detail?id=2618674240","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618674240?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:21","pubTimestamp":1773087660,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies gained Monday, as the Russell 2000 Index gained 1.1%, and the S&P Small Cap 600 Index was up 0.5%.Among companies with a market value of $1 billion to $6.7 billion, Xenon Pharmaceuticals Inc. was the best performer during the session, surging 50%, followed by Hims & Hers Health Inc., which surged 41%. Dianthus Therapeutics Inc. shares jumped 22%, AXT Inc. jumped 19%, and shares of Dyne Therapeutics Inc. jumped 19%.Olema Pharmaceuticals Inc. was the biggest laggard, dropping 26%, followed by shares of Evolution Metals & Technologies Corp., which dropped 16%. Shares of Oric Pharmaceuticals Inc. dropped 15%, Braiin Ltd. shares tumbled 13%, and Trevi Therapeutics Inc. tumbled 12%.Major U.S. stock indexes increased Monday as the Nasdaq Composite Index gained 1.4%. Meanwhile, the S&P 500 Index gained 0.8%, and the Dow Jones Industrial Average increased 0.5%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2618674735","title":"Xenon Pharmaceuticals announces $500M common shares offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618674735","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618674735?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:05","pubTimestamp":1773086745,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) announced that it has commenced an underwritten public offering of $500M of its common shares, pursuant to its existin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-announces-500m-common-shares-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-announces-500m-common-shares-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2618671737","title":"Xenon Pharmaceuticals Inc - Commences $500 Mln Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618671737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618671737?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA4TMBH2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2618671713","title":"Press Release: Xenon Pharmaceuticals Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618671713","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618671713?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086460,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026  -- Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that it has commenced an underwritten public offering of $500.0 million of its common shares, pursuant to its existing shelf registration statement. All of the common shares in this offering are being offered by Xenon. In addition, Xenon intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $75.0 million of common shares at the public offering price, less the underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair are acting as joint book-running managers f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109391861.USD","LU0683600562.USD","LU0316494557.USD","LU0029864427.USD","LU2764263203.CNY","LU0787776722.HKD","V","LU0158827781.USD","SG9999017495.SGD","LU0353189763.USD","LU2461242641.AUD","LU1989772923.USD","LU0158827948.USD","LU1366333091.USD","LU2404859667.USD","LU0511384066.AUD","GB00B4QBRK32.GBP","LU0868494617.USD","LU1974910355.USD","LU2244417387.USD","LU0640476718.USD","LU1934455277.USD","LU2023250843.SGD","LU0354030511.USD","LU0444971666.USD","SGXZ31699556.SGD","LU1236620750.USD","LU1852331112.SGD","LU0170899867.USD","XENE","LU2764262908.HKD","IE00BQXX3F31.USD","LU1363072403.SGD","LU0868494708.USD","LU0557290698.USD","LU0348723411.USD","LU2264538146.SGD","LU2361044949.HKD","USA","BK4598","LU0057025933.USD","LU2720916845.USD","SGXZ99366536.SGD","BK4534","LU1988902786.USD","LU0006306889.USD","LU0971096721.USD","LU1934455194.USD","LU1400636657.SGD","LU2506952097.USD"],"gpt_icon":0},{"id":"2618894679","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2618894679","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618894679?lang=en_us&edition=fundamental","pubTime":"2026-03-10 02:42","pubTimestamp":1773081760,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics  said Monday it has struck a deal to sell shares and pre-funded warrants to investors, including Venrock Healthcare Capital Partners and Commodore Capital, to raise about $160 million. It expects to close the deal March 11.Shares soared 46% as intraday trading volume surged to over 36.4 million from a daily average of about 676,000.Dianthus Therapeutics  said early Go decision was reached in phase 3 trial of claseprubart in chronic inflammatory demyelinating polyneuropathy after 20 confirmed responders were achieved with less than 40 planned participants completing open-label part A of the trial. The firm also reported Q4 results.Shares jumped 18% as intraday trading volume climbed to more than 3.2 million from a daily average of about 795,000.Xenon Pharmaceuticals  reported \"positive\" topline results from its phase 3 study of azetukalner in focal onset seizures.Shares soared 46% as intraday trading volume jumped to over 9.5 million from a daily average of roughly ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RLMD","XENE","BK4007","BK4139","DNTH"],"gpt_icon":0},{"id":"2618820679","title":"A Look At Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Drift Without Clear Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2618820679","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618820679?lang=en_us&edition=fundamental","pubTime":"2026-03-10 02:19","pubTimestamp":1773080381,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals: Event Trigger and Recent Share Performance\nXenon Pharmaceuticals (XENE) shares recently moved without a clear single headline catalyst, which can prompt investors to reassess the neuroscience focused biopharmaceutical company and its current trading levels.\nSee our latest analysis for Xenon Pharmaceuticals.\nAt a share price of $41.94, Xenon’s short term trading has been relatively soft, with a 30 day share price return of 1.35% and a year to date share price return of a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-recent-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-recent-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XENE","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xenon-pharma.com;investor.xenon-pharma.com","stockEarnings":[{"period":"1week","weight":0.0065},{"period":"1month","weight":0.2398},{"period":"3month","weight":0.2384},{"period":"6month","weight":0.4621},{"period":"1year","weight":0.5966},{"period":"ytd","weight":0.239}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.008322},{"month":2,"riseRate":0.75,"avgChangeRate":0.076063},{"month":3,"riseRate":0.25,"avgChangeRate":-0.045377},{"month":4,"riseRate":0.545455,"avgChangeRate":0.022894},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.037416},{"month":6,"riseRate":0.454545,"avgChangeRate":0.032291},{"month":7,"riseRate":0.363636,"avgChangeRate":0.01913},{"month":8,"riseRate":0.727273,"avgChangeRate":0.07504},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.05886},{"month":10,"riseRate":0.454545,"avgChangeRate":0.054946},{"month":11,"riseRate":0.727273,"avgChangeRate":0.050412},{"month":12,"riseRate":0.666667,"avgChangeRate":0.089745}],"exchange":"NASDAQ","name":"Xenon Pharmaceuticals","nameEN":"Xenon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenon Pharmaceuticals,XENE,Xenon Pharmaceuticals股票,Xenon Pharmaceuticals股票老虎,Xenon Pharmaceuticals股票老虎国际,Xenon Pharmaceuticals行情,Xenon Pharmaceuticals股票行情,Xenon Pharmaceuticals股价,Xenon Pharmaceuticals股市,Xenon Pharmaceuticals股票价格,Xenon Pharmaceuticals股票交易,Xenon Pharmaceuticals股票购买,Xenon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}